Objectives. Prostate cancer recurrence, evidenced by rising prostate-specific antigen (PSA)
levels after radical prostatectomy, is an increasingly prevalent clinical problem in need of
new treatment options. Preclinical studies have suggested that for tumors in general,
settings of minimal cancer volume may be uniquely suitable for recombinant vaccine therapy
targeting tumor-associated antigens. A clinical study was undertaken to evaluate the safety
and biologic effects of vaccinia-PSA (PROSTVAC) administered to subjects with …